Why CMC readiness is becoming central to biopharma licensing deals

CMC readiness is becoming critical in biopharma licensing as partners demand proof an asset can be transferred, scaled and supplied As licensing expands, manufacturing evidence is becoming a decisive test of asset value and deal confidence. CMC readiness is becoming a decisive factor in biopharma licensing. Credit: Shutterstock Biopharma licensing is becoming more operational. Buyers and partners still begin with the quality of the science, but they also need evidence that an asset can be transferred, scaled and supplied without weakening its commercial potential. For outsourced assets, the right contract development and manufacturing organisation (CDMO) can strengthen confidence in technical,…

Source: Clinical Trials Arena